Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072

Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy

(2012) Camilla Molich Hoff   ACTA ONCOLOGICA

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

(2012) S Sleijfer et al.   BRITISH JOURNAL OF CANCER

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for Phase I oncology trial participants – Reply to Fussenich et al.: A new, simple and objective prognostic score for Phase I cancer patients

(2011) David Olmos et al.   EUROPEAN JOURNAL OF CANCER

Pazopanib: a promising new agent in the treatment of soft tissue sarcomas

(2011) Bernd Kasper et al.   Future Oncology

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

(2011) Patrick Schöffski et al.   LANCET ONCOLOGY

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

(2009) Isabelle Ray-Coquard et al.   CANCER RESEARCH

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

(2009) Stefan Sleijfer et al.   EUROPEAN JOURNAL OF CANCER

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor†

(2008) Philip A. Harris et al.   JOURNAL OF MEDICINAL CHEMISTRY